GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE333nnn/GSE333537/primaryOK200TranscriptomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE333537GEOGSEfalsePhase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapyVCN-01 is a hyaluronidase-expressing oncolytic adenovirus that increases immune checkpoint antibody tumor uptake in mice. VCN-01 was evaluated with durvalumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients refractory to anti-PD-(L)12026/06/03GSE333537GSM9768156GSM9768134GSM9768155GSM9768133GSM9768136GSM9768135GSM9768138GSM9768137GSM9768139GSM9768150GSM9768152GSM9768130GSM9768151GSM9768132GSM9768154GSM9768153GSM9768131GSM9768123GSM9768145GSM9768144GSM9768122GSM9768147GSM9768125GSM9768146GSM9768124GSM9768149GSM9768127GSM9768126GSM9768148GSM9768129GSM9768128GSM9768141GSM9768140GSM9768143GSM976814218573333537Homo sapiens